Clinical Trials in Los Angeles

Showing 1401-1420 of 16,901 trials

Early Feeds in Gastroschisis

NCT06878950

This study aims to evaluate the feasibility of initiating early feeds in neonates with gastroschisis, a condition where infants are born with their intestines outside the body.

Gastroschisis

University of California, Davis20 participantsStarted Feb 2025

Los Angeles, California, United States • Sacramento, California, United States

Active Not RecruitingPhase 2< 1 mile

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

NCT03607890

The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins38 participantsStarted Nov 2018

Los Angeles, California, United States • Baltimore, Maryland, United States

Active Not RecruitingPhase 2< 1 mile

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081

The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

COVID-19

QuantumLeap Healthcare Collaborative1,500 participantsStarted Jul 2020

Birmingham, Alabama, United States • Davis, California, United States • Irvine, California, United States +33 more locations

Early Feeds in Gastroschisis

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Find Trials by Condition in Los Angeles

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Empathic Communication Skills (ECS) Training

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

An International Observational Study of Adults With Acute Infection

A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)

Safety of RSV Preventive Monoclonal Antibody

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)